NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the ...

Moderna Inc. (NASDAQ:MRNA) is one of the high short interest stocks to buy right now. On November 20, Moderna announced that ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...

Super Micro's headwinds stemming from AI-bubble fears contrast with improving compliance, new Nvidia-powered products, and a ...

The decision applies to adolescents and adults and aligns with earlier US authorization for higher-risk groups.

Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the ...

Vinay Prasad, a top FDA official, blamed COVID shots for playing a role in the deaths of 10 children in a memo he sent to ...

Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s ...

While the FDA and the Centers for Disease Control and Prevention (CDC) have signed off on updated COVID vaccines for this season, Moderna is already reportedly preparing for lower demand for its shot.

Ever since the COVID-19 pandemic began to ease, Moderna has weathered a sharp revenue downturn. But a new FDA approval shows that the company's scientific engine is no one trick pony. Moderna's ...

Forbes contributors publish independent expert analyses and insights. Jack is a career business journalist an an award-winning podcast host. Speed-to-market has always been critical in the life ...

Moderna (NASDAQ: MRNA) provided updates on the manufacturing of its Covid-19 vaccine, noting that it was increasing the baseline production estimate for this year to 600 million doses, 100 million ...